BackNahdi Medical Company Overview

Nahdi Medical Company EBIT

Latest ebit for 4164.SR: $700M, below the sector sector average of $2.3T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$9.99M
↓ 104.9% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$702.15M
↓ 24.7% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Nahdi Medical Company (4164.SR) FAQ

The latest EBIT for 4164.SR is $700M as of September 2026. That compares with $930M in the prior-year period — down 24.7% year over year. That is below the sector sector average of $2.3T. Investors often review this figure alongside Nahdi Medical Company's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4164.SR's EBIT moved from $930M to $700M — a 24.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nahdi Medical Company's operating scale or balance-sheet position.

Against its sector companies, 4164.SR currently prints $700M for EBIT, while the sector average sits near $2.3T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Nahdi Medical Company's growth, margins, and balance sheet.

A EBIT figure of $700M for 4164.SR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.3T. Explore the charts below for those layers of context.

After noting 4164.SR's EBIT ($700M), review year-over-year change from $930M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers